类风湿性关节炎与强直性脊柱炎的X线诊断

作者通过复习文献 ,着重从临床和X线角度论述了类风湿性关节炎和强直性脊柱炎。认为两者是完全不同的独立疾病。类风湿性关节炎属胶原系统疾病 ,女性多见 ,常侵及周围小关节 ,X线表现为关节肿胀、骨质疏松、关节间隙早期增宽 ,后期变窄 ,关节脱位、强直、畸形。强直性脊柱炎属关节疾患 ,青年男性多见 ,中轴骨首先受累 ,X线几乎 10 0 %有骶髂关节改变 ,方型椎和韧带骨赘是其特征性X线表现     

强直性脊柱炎并发虹睫炎易感性与LMP2和LMP7基因多态性的探讨

目的　研究LMP基因多态性与强直性脊柱炎并发虹睫炎发病的关系.方法　应用PCR对正常人和病人进行HLA-B27检测以及LMP2和LMP7扩增.CfoI进行限制性酶切图谱分析.结果　强直性脊柱炎有虹睫炎(AS+AAU)病史以及单纯虹睫炎(AAU)患者LMP2基因BB纯合型较正常人以及强直性脊柱炎(AS)患者明显增高(P＜0.05).AS+AAU患者BB型OR＝3.6,AAU患者BB型OR＝5.83.LMP7基因多态性无明显差别.结论　在我国汉人中,LMP2基因多态性与AS+AAU以及AAU发病存在明显相关关系.     

Takayasu’s arteritis occurring under TNF blockers in a patient with spondyloarthritis: is it an association or a paradoxical effect?

Coexistence of spondyloarthritis (SpA) and Takayasu’s arteritis is not a common finding, but such cases have been discussed, particularly in the context of choice of therapy. Inhibition of inflammation by tumor necrosis factor inhibitors (TNFi) is a key aspect of the treatment of SpA and also positive effects of such treatment in concomitant large vessel vasculitis have been reported. However, TNFi is also associated with the possibility of initiating vasculitis.The present article based on a case study and the available literature is an attempt to discuss coexistence of these two diseases and the impact of treatment with biological drugs from the anti-TNF group in the course of SpA with Takayasu’s arteritis.     

Direct anti-proliferative effect of adipose-derived mesenchymal stem cells of ankylosing spondylitis patients on allogenic CD4+ cells

ObjectivesT-cell-mediated adaptive immunity contributes to the development and persistence of ankylosing spondylitis (AS). Mesenchymal stromal/stem cells (MSCs) have immunomodulatory potential and are able to inhibit T-cell proliferation, but their functionality in AS patients is relatively unknown. The aim of the study was to assess the direct anti-proliferative effects of MSCs isolated from subcutaneous abdominal adipose tissue of AS patients (AS/ASCs) on allogeneic T lymphocytes, using commercially available ASC lines from healthy donors (HD/ASCs) as a control.Material and methodsCD3+CD4+ T-cells were isolated from peripheral blood of healthy blood donors, activated with anti-CD3/CD28 beads, and co-cultured for 5 days with untreated and TNF+IFN-γ pre-stimulated HD/ASCs (5 cell lines) and AS/ASCs, obtained from 11 patients (6F/5M). The proliferative response of T-cells was analysed by flow cytometry, while the concentrations of kynurenines, prostaglandin E2 (PGE-2), interleukin 10 (IL-10), and interleukin 1 receptor antagonist (IL-1Ra) were measured spectrophotometrically or using a specific enzyme-linked immunosorbent assay (ELISA).ResultsHD/ASCs and AS/ASCs similarly reduced the T-cell proliferation response, i.e. the percentage of proliferating cells, the proliferation, and replication indices, and these effects were dependent mostly on soluble factors. In the co-cultures of activated CD4+ T-cells with HD/ASCs and AS/ASCs significant increases of kynurenines, PGE-2, and IL-1Ra, but not IL-10, production were observed. The release of these factors was dependent either on cell-to-cell contact (IL-10, IL-1Ra) or soluble factors (kynurenines, PGE-2). There was a moderate to strong negative correlation between T-cell proliferative response, and the concentrations of kynurenines, PGE-2, and IL-10, but not IL-1Ra. This association was more evident in the case of TI-treated AS/ASCs than HD/ASCs.ConclusionsAS/ASCs, similar to HD/ASCs, exert a direct effective anti-proliferative impact on CD4+ T cells, acting via soluble factors that are released in cell contact-dependent (IL-10) and independent (kynurenines, PGE-2) pathways. Thus, our results suggest that AS/ASCs are potentially useful for therapeutic application.     

80例强直性脊柱炎临床X线分析

目的：分析和研究强直性脊柱炎的临床Ｘ线检查诊断方法,Ｘ线分级、分期的表现及在诊断中的重要性,方法：对８０例强直性脊柱炎患者进行Ｘ摄片分级,分期,结合血沉（ＥＳＲ）,Ｃ－反应蛋白（ＣＲＰ）和ＨＬＡ－Ｂ２检查诊断。并进行统计学分析。结果：９０％患者ＨＬＡ－Ｂ２阳性,６０％血沉增快,骶髂关节和髋关节片以２级改变为主,腰椎病变以早、中期Ｘ线病变者较多。结论：强直性脊柱炎以青壮年男性为多见,ＨＬＡ－Ｂ２阳性     

联合给药法治疗强直性脊柱炎

目的 采用氨甲喋呤（ＭＴＸ）、抑氮磺胺吡啶（ＳＡＳＰ） 非甾体类药（ＮＳＡＩＤｓ）“递减法”联合给药治疗７８例强直性脊柱炎（ＡＳ的临床疗效观察。方法 ＳＡＳＰ０．５ｇ,２次／日,服１周后改为０．７５ｇ,２次／日,第２周后改为１．０ｇ,２次／日,以后每周１．０ｇ,２次／日,疗程２年,ＭＴＳ５ｍｇ,１次／周,每周递增５ｍｇ,加量至１５～２０ｍｇ／周时维持０．５～１年,ＮＳＡＩＤｓ疗程为３个月左右减半量     

儿童胸椎化脓性脊柱炎误诊分析（附1例报告）

<正>化脓性脊柱炎（Pyogenic spondylitis）是一种相对少见的脊柱感染性疾病,主要包括化脓性椎间盘炎、脊柱骨髓炎、椎间盘炎合并椎体骨髓炎以及硬膜外脓肿。有证据表明,近年来,化脓性脊柱炎的发病率和致死率正逐渐升高。化脓性脊柱炎好发于老年人和有慢性疾病患者[1],儿童化脓性脊柱炎患者十分罕见,因而容易漏诊误诊。本文回顾2017年9月6日我院收治1例10岁化脓性脊柱炎患者,对其误诊及漏诊原因进行分析,报道如下：     

停用雷公藤糖浆精子密度可复性调查

目的 分析服用及停用雷公藤糖浆后患者精子密度的变化及生育恢复情况。方法 采用ＷＨＯ的标准,对３３例服用雷公藤糖浆的强直性脊柱炎２的精液进行分析,并调查和随访其生育情况。结果 服药期间,３３例患者精液检查均 子密度为零或接近零的记录;停药１２０ｄ以上,精子密度均见显著提高;３３例雷公藤糖浆服用者中,１３例的妻子有孕育史。结论雷公藤糖浆可致男性精子密度降低至零,停药后可以恢复生育。     

强直性脊柱炎从肾论治的证治探讨

强直性脊柱炎的主要病因病机是肾虚督脉空虚为本，邪实外侵为标，中医辨治应从肾论治，根据其临床特点，分为中枢型、周围型、迁延型；中药蠲偻方治疗本病，以补肾强督为主，佐以活血脉，壮筋骨，祛风除湿，通筋活络利关节。     

美洛昔康栓剂治疗强直性脊柱炎62例

目的:评价美洛昔康栓剂治疗强直性脊柱炎(AS)患者的疗效和安全性。方法:126例AS患者,随机分为治疗组62例和对照组64例,分别应用美洛昔康栓和美洛昔康片,剂量均为15mg·d~(-1),疗程6周。结果:治疗组与对照组的总有效率分别为84.49％和77.42％,2组比较差异无显著性(P>0.05),2组总计不良事件发生率分别为12.90％和21.87％,不良事件主要集中在胃肠道,无严重不良事件发生。结论:美洛昔康栓对AS患者的止痛效果及安全性与美洛昔康片类似,且总计不良事件发生率和单项最高不良事件发生率均低于片剂组。